Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.85B |
| 2 |
Linde
LIN
|
+$1.14B |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$653M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$629M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$591M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortive
FTV
|
+$1.17B |
| 2 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$981M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$416M |
| 4 |
Amazon
AMZN
|
+$402M |
| 5 |
State Street Industrial Select Sector SPDR ETF
XLI
|
+$338M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.9% |
| 2 | Healthcare | 5.31% |
| 3 | Financials | 5.25% |
| 4 | Communication Services | 4.61% |
| 5 | Consumer Discretionary | 4.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4676
Alaunos Therapeutics
TCRT
$4.88M
| $152K | ﹤0.01% |
544
-409
| -43% | -$162K |
|
|
JHG
4677
DELISTED
Janus Henderson
JHG
| $151K | ﹤0.01% |
7,283
-52,391
| -88% | -$1.2M |
|
|
HAPN
4678
Happen Inc
HAPN
$2.27B
| $151K | ﹤0.01% |
11,506
-19,367
| -63% | -$319K |
|
|
RDFN
4679
PUT
DELISTED
Redfin
RDFN
| $151K | ﹤0.01% |
10,500
-2,200
| -17% | -$34.9K |
|
4680
PUT
ProShares UltraShort Russell2000
TWM
$40.8M
| $151K | ﹤0.01% |
+365
| New | +$126K |
|
4681
HCI Group
HCI
$2.31B
| $150K | ﹤0.01% |
2,940
-5,224
| -64% | -$256K |
|
4682
PUT
Medifast
MED
$128M
| $150K | ﹤0.01% |
1,200
-10,100
| -89% | -$1.73M |
|
4683
CALL
NNN REIT
NNN
$8.87B
| $150K | ﹤0.01% |
3,100
-1,800
| -37% | -$85.8K |
|
4684
Houlihan Lokey
HLI
$9.23B
| $149K | ﹤0.01% |
4,052
-14,568
| -78% | -$594K |
|
4685
PUT
iShares Core S&P Mid-Cap ETF
IJH
$128B
| $149K | ﹤0.01% |
4,500
+2,000
| +80% | +$73K |
|
4686
PUT
Raymond James Financial
RJF
$34.8B
| $149K | ﹤0.01% |
3,000
-221,400
| -99% | -$11.8M |
|
4687
CALL
Group 1 Automotive
GPI
$3.14B
| $148K | ﹤0.01% |
2,800
+2,500
| +833% | +$139K |
|
|
ADMS
4688
DELISTED
Adamas Pharmaceuticals
ADMS
| $148K | ﹤0.01% |
17,387
+8,118
| +88% | +$106K |
|
4689
Stoneridge
SRI
$201M
| $147K | ﹤0.01% |
5,957
-10,554
| -64% | -$268K |
|
|
FPRX
4690
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $147K | ﹤0.01% |
15,848
-22,506
| -59% | -$268K |
|
4691
PUT
CoreCivic
CXW
$3.14B
| $146K | ﹤0.01% |
8,200
-3,000
| -27% | -$65.9K |
|
4692
Willdan Group
WLDN
$1.29B
| $146K | ﹤0.01% |
4,177
+1,115
| +36% | +$38.2K |
|
4693
PUT
Axalta
AXTA
$7.93B
| $145K | ﹤0.01% |
6,200
+4,000
| +182% | +$99.4K |
|
|
BELFB
4694
Bel Fuse Inc Class B
BELFB
$4.13B
| $145K | ﹤0.01% |
7,864
-5,743
| -42% | -$130K |
|
4695
CALL
Cimpress
CMPR
$2.37B
| $145K | ﹤0.01% |
1,400
-2,900
| -67% | -$337K |
|
4696
Cytokinetics
CYTK
$10.2B
| $145K | ﹤0.01% |
23,049
-32,952
| -59% | -$242K |
|
4697
PUT
Ericsson
ERIC
$33.6B
| $145K | ﹤0.01% |
16,400
+15,200
| +1,267% | +$132K |
|
4698
CALL
O-I Glass
OI
$1.05B
| $145K | ﹤0.01% |
8,400
-1,000
| -11% | -$17.5K |
|
4699
Q32 Bio
QTTB
$457M
| $145K | ﹤0.01% |
361
+144
| +66% | +$54.5K |
|
|
RRD
4700
DELISTED
RR Donnelley & Sons Co.
RRD
| $145K | ﹤0.01% |
36,792
-54,171
| -60% | -$282K |
|
Similar funds
Barclays's Q4 2018 Portfolio in Review
As of Q4 2018, Barclays held 7,834 positions worth $129B, down 10% from $144B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Barclays deployed $5.69B of net new capital in Q4 2018, opening 489 new positions and adding to 2,471 existing holdings. Its largest new stake was Linde: 7,232,686 shares worth $1.13B.
By sector, the portfolio is most concentrated in Technology at 6.9% of assets, down from 8.2% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Fortive, an estimated $1.17B trimmed.
- Barclays's largest Q4 2018 buy was Linde: 7,232,686 shares worth $1.13B.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q4 2018, an estimated $1.85B increase.
- Barclays's biggest Q4 2018 reduction was Fortive, cutting an estimated $1.17B.
- Barclays fully exited Energy Transfer Partners, L.P. in Q4 2018, selling an estimated $184M.
- Barclays's ten largest holdings make up 32% of its $129B portfolio in Q4 2018.
- Barclays opened 489 new positions and closed 777 in Q4 2018.
- Barclays's portfolio value fell 10% quarter-over-quarter to $129B.
Based on Barclays's 13F filing for Q4 2018, filed 14 Feb 2019.